DelveInsight’s “Group B Streptococcus Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Group B Streptococcus market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Group B Streptococcus drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Group B Streptococcus treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Group B Streptococcus: An Overview
Group B strep (streptococcus) is a common bacterium, often carried in the intestines or lower genital tract. The bacterium is usually harmless in healthy adults; however, in newborns, it can cause a serious illness known as Group B Streptococcus (GBS).
Group B Streptococcus can also cause dangerous infections in adults with certain chronic medical conditions, such as diabetes or liver disease. Also, older adults are at increased risk of illness due to group B strep. Group B Streptococcus infections during pregnancy may lead to preterm labor or if the baby is infected while in the uterus, stillbirth, although pregnant women who tested positive for Group B Streptococcus infection are usually asymptomatic.
In infants, illness caused by Group B Streptococcus can occur within 6 h of birth (early onset) — or weeks or months after birth (late onset). Fever, low body temperature, difficulty feeding, sluggishness, limpness or weak muscle tone, difficulty breathing, irritability, jitteriness, seizures, rash, and others are some of the signs and symptoms of Group B Streptococcus.
Many adults carry Group B Streptococcus in their bodies, usually in the bowel, rectum, bladder, or throat, and have no signs or symptoms. In some cases, however, Group B Streptococcus can cause a urinary tract infection or other more serious infections.
Group B Streptococcus Market Key Facts
In 2022, the Group B Streptococcus market size was the highest in the US among the 7MM, accounting for approximately USD 139 million, which is expected to increase by 2040.
There are currently no approved therapies in the market to treat Group B Streptococcus, antibiotics, and current off-label prophylaxis used for managing the disease accounted for approximately USD 194 million in 2022 in 7MM as per our analysis.
There were 0.2 million incident cases of Group B Streptococcus estimated to have occurred in the 7MM in 2022, of which 0.15 million cases come from the US alone and are projected to increase during the forecasted period.
Type-specific incident cases of Group B Streptococcus infection are segmented into invasive and non-invasive Group B Streptococcus infection, among which the non-invasive pool has a higher incidence.
Nearly 2 million pregnant women were estimated to have Group B Streptococcus colonization in the 7MM, which is expected to reduce in the forecasted years due to decreasing pregnancy trends in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Group B Streptococcus pipeline therapies. It also thoroughly assesses the Group B Streptococcus market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Group B Streptococcus drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Group B Streptococcus Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Group B Streptococcus epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Group B Streptococcus epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Group B Streptococcus Epidemiology, Segmented as –
Total incident cases of Group B Streptococcus infection in the 7MM
Type-specific incident cases of Group B Streptococcus infection in the 7MM
Age-specific incident cases of Group B Streptococcus infection (invasive and non-invasive) in the 7MM
Number of pregnant women with Group B Streptococcus colonization in the 7MM
Group B Streptococcus Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Group B Streptococcus market or expected to be launched during the study period. The analysis covers the Group B Streptococcus market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Group B Streptococcus drugs based on their sale and market share.
The report also covers the Group B Streptococcus pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Group B Streptococcus companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Group B Streptococcus Market Will Evolve and Grow by 2032 @
Group B Streptococcus Therapeutics Analysis
The current treatment spectra include empiric treatment, specific treatment, supportive treatment, adjunctive treatment, and treatments targeting recurrent infections where the therapeutic management oscillates between prophylaxis and curative treatments. The current treatment landscape lacks approved curative or prophylactic measures and is mainly accredited to off-labels.
The dynamics of the Group B Streptococcus market are anticipated to change in the coming years owing to the rising awareness of the disease, and the development of vaccines across the world.
Group B Streptococcus Companies Actively Working in the Therapeutics Market Include
And Many Others
Emerging and Marketed Group B Streptococcus Therapies Covered in the Report Include:
Group B Streptococcus-NN/NN2: Minervax ApS
PF-06760805/GBS 6: Pfizer
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Group B Streptococcus Competitive Intelligence Analysis
4. Group B Streptococcus Market Overview at a Glance
5. Group B Streptococcus Disease Background and Overview
6. Group B Streptococcus Patient Journey
7. Group B Streptococcus Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Group B Streptococcus Treatment Algorithm, Current Treatment, and Medical Practices
9. Group B Streptococcus Unmet Needs
10. Key Endpoints of Group B Streptococcus Treatment
11. Group B Streptococcus Marketed Therapies
12. Group B Streptococcus Emerging Drugs and Latest Therapeutic Advances
13. Group B Streptococcus Seven Major Market Analysis
14. Attribute Analysis
15. Group B Streptococcus Market Outlook (In US, EU5, and Japan)
16. Group B Streptococcus Companies Active in the Market
17. Group B Streptococcus Access and Reimbursement Overview
18. KOL Views on the Group B Streptococcus Market
19. Group B Streptococcus Market Drivers
20. Group B Streptococcus Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Primary Immune Deficiency (PID) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Primary Immune Deficiency market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Primary Immune Deficiency market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States